Enterprise Europe Network (Profile ID: TOIT20161205005)

Short description of advertisement: 
Italian start-up developing technologies for the production of nano/micro structured 100% silk fibroin medical devices for in-vivo tissue regeneration is looking for technical and research partners.

Italian start-up in the field of human tissue regeneration has developed a new device for the regeneration of small blood vessels by leveraging the biomimetic properties and the mechanical advantages of silk.
The same technology is suitable to several applications as peripheral nerves, tendons and ligaments, skin, and other tensile stressed tissues. The company is looking for partners for research and technical cooperation in the ISO/FDA approval pathway.

The offerer of the present technology is a medtech start-up whose first and main goal is to develop an innovative technology for the production of medical implantable devices made of silk fibroin for the in-vivo regeneration of human tissues and marketing it for human indications through licensing agreements. The technology is based on the coupling of electrospun matrices (ES) for boosting the biological and biomimetic properties of silk fibroin and textile matrices (TEXT) for the high mechanical tensile properties.
The company has designed a new device for the regeneration of small blood vessels. About 560k/year coronary artery bypass graft surgeries (CABG) are performed in OECD countries. The current golden standard for CABG is autograft (mainly saphenous vein, umbilical vein and mammary artery) and very often more than one graft is required for each procedure. However, autografts are not always available and present several drawbacks: so, there is a global urgent need for man-made grafts. Very few synthetic grafts are on the market and, due to their very poor results, they are used only when autografts previously failed. There is also a need for man-made solutions for peripheral blood vessels, like saphenous veins and carotids. For those vessels there are no autografts available and small calibre synthetic grafts fail in restoring the bloodstream. This innovative nanotechnology stimulates faster natural human tissue regeneration, with no rejection risks or use of drugs. In addition to that, it is cheaper than other synthetic grafts, allows for easy surgery and doesn’t produce any dangerous degradation product in the patient’s body.
In the developing pipeline other devices (peripheral nerves, tendons and ligaments, skin, dura madre, and other tensile stressed tissues) will be developed as soon as possible using the same technologies.
Different technologies are under investigation to further increase the addressable markets. This new technology lands in the tissue engineering market, which is worth globally €85bn.
The company has received and is receiving a number of VC funding and prizes which grant financial sustainability of the project; its goal now is to find a stable market for its new technology and explore other possible market applications.
The company is looking for strategic partners to further develop this technology, speed up the approval pathway, improve the investment readiness of the company, strengthen its long term sustainability, and develop new technologies based on the use of silk fibroin in biomed and biotech fields. Partners could be research or technical partners for support and cooperation in the ES-TEXT products development and validation; investigation and study of new technologies for biomed and biotech fields, interested in signing a research cooperation agreement and/or a technical cooperation agreement.



For more information please contact Enterprise Europe Network Latvia.

Contact person: 
Enterprise Europe Network Latvia
Contact languages: 
Perses Street 2, Riga, LV-1442, Latvia
info [at] een [dot] lv
Valid till: 
Saturday, 6 January, 2018